Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H16O4 |
Molecular Weight | 272.2958 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(O)=C(C=C1)C2COC3=CC(O)=CC=C3C2
InChI
InChIKey=XRVFNNUXNVWYTI-UHFFFAOYSA-N
InChI=1S/C16H16O4/c1-19-13-4-5-14(15(18)8-13)11-6-10-2-3-12(17)7-16(10)20-9-11/h2-5,7-8,11,17-18H,6,9H2,1H3
Molecular Formula | C16H16O4 |
Molecular Weight | 272.2958 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26938776
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26938776
Vestitol is an isoflavonoid isolated from Brazilian red propolis with potential anti-inflammatory activity. Vestitol showed inhibitory activity on neutrophil migration induced by different inflammatory stimuli. Its activity is related to inhibition or decrease of the release of the chemokines CXCL1/KC and CXCL2/MIP-2 by resident macrophages, resulting in diminished rolling and adhesion of leukocytes in the mesenteric microcirculation. Vestitol, may have potential therapeutic application to modulate inflammation processes, such as those involved with periodontal diseases.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:1990266 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26938776 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26938776
Mice were pre-treated with sc administration of vestitol (1, 3, or 10 mg/kg) 30 min prior to ip injection of LPS (300 ng/cavity). The mice were killed 6 h after the challenge (LPS) and cells from the peritoneal cavity were harvested. Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26938776
Vestitol activity was evaluated in Neutrophil Chemotaxis assay. Neutrophils isolated from the bone marrow of mice were treated with Vestitol (3 or 10 mkM) for 60 min. There was a reduction on the chemotaxis of CXCL2/MIP-2 or LTB4-induced neutrophils after pre-treatment with the Vestitol.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:30:30 GMT 2023
by
admin
on
Sat Dec 16 08:30:30 GMT 2023
|
Record UNII |
Z244UVZ669
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
56701-24-7
Created by
admin on Sat Dec 16 08:30:30 GMT 2023 , Edited by admin on Sat Dec 16 08:30:30 GMT 2023
|
PRIMARY | |||
|
Z244UVZ669
Created by
admin on Sat Dec 16 08:30:30 GMT 2023 , Edited by admin on Sat Dec 16 08:30:30 GMT 2023
|
PRIMARY | |||
|
92503
Created by
admin on Sat Dec 16 08:30:30 GMT 2023 , Edited by admin on Sat Dec 16 08:30:30 GMT 2023
|
PRIMARY |